Story by: Sharon Spruell
March 1, 2023
Ferrara-Buist Contractors is a company that is committed to making a difference in the world. As a business, we believe that we have a responsibility to give back to our community and support those who are in need. That’s why we have chosen to sponsor Ashley McCormick, a team member for The Leukemia & Lymphoma Society’s Visionaries of the Year campaign.
The Leukemia & Lymphoma Society (LLS) is a global leader in the fight against blood cancer. They are committed to finding a cure for leukemia, lymphoma, Hodgkin’s disease, and myeloma, as well as improving the lives of patients and their families. LLS funds cutting-edge research that leads to breakthroughs in immunotherapy, genomics, and personalized medicine. They also provide free education and support for blood cancer patients and their families, including personalized, one-on-one support, assistance with identifying and enrolling in clinical trials, and more. Additionally, LLS mobilizes thousands of advocates to drive policy changes that accelerate the development of new cancer treatments and break down barriers to care.
Ashley McCormick is a visionary who shares LLS’s mission to create a world without blood cancers. As a team member for The Leukemia & Lymphoma Society’s Visionaries of the Year campaign, Ashley is working to make the largest impact possible for LLS’s mission. With the help of Ferrara-Buist Contractors and other sponsors, Ashley is raising money to support LLS’s research and patient services.
Ferrara-Buist Contractors is proud to support Ashley McCormick and The Leukemia & Lymphoma Society’s Visionaries of the Year campaign. As a business, Ferrara-Buist Contractors understands the importance of corporate social responsibility. We believe that it is our duty to give back to the community that has supported us over the years. By sponsoring Ashley McCormick and supporting The Leukemia & Lymphoma Society’s Visionaries of the Year campaign, we hope to make a difference in the lives of people who are affected by blood cancer.